Lorsque la myasthénie est jugée réfractaire: indications cliniques et stratégies de traitement

Verrouillé
Avatar du membre

Auteur du sujet
Pboulanger Prés.
Administrateur
Administrateur
Messages : 10762
Enregistré le : 02 févr. 2010 18:41
14
Localisation  : La Chapelle en Serval F-60520
Genre :
Zodiaque :
Âge : 67
    Windows 10 Firefox

Lorsque la myasthénie est jugée réfractaire: indications cliniques et stratégies de traitement

Message par Pboulanger Prés. »

:hi:

:arrow: Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/29403543

[ligne][/ligne]

Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en

Image

[ligne][/ligne]

When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies.
Mantegazza R1, Antozzi C2.
Ther Adv Neurol Disord. 2018 Jan 18;11:1756285617749134. doi: 10.1177/1756285617749134. eCollection 2018.


Abstract

The prognosis for patients with myasthenia gravis (MG) has improved significantly over the past half century, including substantial reductions in mortality and morbidity.

However, approximately 10% of patients fails to respond adequately to current therapies and are considered treatment refractory, or treatment intolerant, and up to 80% have disease that fails to achieve complete stable remission.

Although patients with autoantibodies to muscle-specific tyrosine kinase (anti-MuSK positive) are more likely to become treatment refractory than those with autoantibodies to the acetylcholine receptor (anti-AChR positive), each of these serotypes is substantially represented in the refractory MG population.

Other risk factors for becoming treatment refractory include history of thymoma or thymectomy and female sex.

A modified treatment algorithm for MG is proposed: patients who have disease that fails to respond to the stepwise approach to therapy, are treatment intolerant, or who require chronic rescue measures despite ongoing therapy, should be considered treatment refractory and emerging therapies should be considered.

Three emerging monoclonal antibody-based therapies are discussed: the anti-B-cell agent rituximab; the terminal complement activation inhibitor eculizumab; and belimumab, which targets B-cell activating factor.

Increased understanding of molecular pathophysiology and accurate antibody subtyping in MG should lead to the use of new therapeutic agents and successful management of treatment-refractory patients.

Message d' un membre de l'équipe technique
Pour les utilisateurs d'I-phone
ci-dessous le lien vers Google Trad

https://translate.google.fr/translate?h ... 2F29403543
Message d' un membre de l'équipe technique
Nous utilisons des services automatiques de traduction fournis
par Yandex ou Google.
Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils.
Amicalement,
Image
Verrouillé

Retourner vers « 2018 »